Skip to main content
OpenTrials

Clinical trial condition

Recurrent Fallopian Tube Carcinoma

Explore clinical trials studying Recurrent Fallopian Tube Carcinoma. Study availability and eligibility vary by location and protocol.

81 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Fallopian Tube Carcinoma trial results

Completed

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02315430

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +19 more
Locations
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
  • Alaska Regional Hospital Anchorage, Alaska, United States
View all 410 locations
View Trial Details
Completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01074411

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +41 more
Locations
  • Hartford Hospital Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View all 14 locations
View Trial Details
Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

NCT01305213

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
  • John Muir Medical Center-Concord Campus Concord, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
View all 51 locations
View Trial Details
Completed

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

NCT01468909

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Gynecologic Oncology Group of Arizona Phoenix, Arizona, United States
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
  • Gynecologic Oncology Associates-Newport Beach Newport Beach, California, United States
View all 142 locations
View Trial Details
Completed

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01540565

Conditions
Adnexal Diseases, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, +20 more
Locations
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • John Muir Medical Center-Concord Campus Concord, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Gynecologic Oncology Associates-Newport Beach Newport Beach, California, United States
View all 153 locations
View Trial Details
Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT01459380

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +22 more
Locations
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
View all 13 locations
View Trial Details
Completed

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01489371

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +22 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • University of New Mexico Cancer Center Albuquerque, New Mexico, United States
View Trial Details
Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

NCT01010126

Conditions
Adenocarcinoma, Adnexal Diseases, Adult Hepatocellular Carcinoma, +76 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles County-USC Medical Center Los Angeles, California, United States
View all 61 locations
View Trial Details
Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

NCT00892736

Conditions
Adnexal Diseases, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, +48 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
View Trial Details

Related conditions